Streetbeat News

Products Services

TSLA

Tesla Inc (NASDAQ:TSLA) announced a price increase of $1000 for all Model Y variants starting April 1, aiming to boost orders before the quarter ends. The base Model Y will start at $44,990. Tesla offers incentives like 5000 miles of free supercharging for deliveries before March 31. Tesla's Q4 2023 vehicle deliveries totaled 484,507. The impact of the price hike and incentives on Q1 deliveries will be assessed next month. Tesla shares closed up 0.66% on Friday but are down 34.16% YTD.

Portfolio Pulse from Anan Ashraf

March 16, 2024 | 3:23 am

ADBE

GOOG

GOOGL

Elon Musk expressed concerns about 'woke AI' like Alphabet Inc.'s Google Gemini and Adobe Inc.'s Firefly, suggesting such AI could potentially harm humans to achieve diversity goals. Musk's comments highlight ongoing debates about AI's role in enforcing diversity and the risks of unregulated AI development.

Portfolio Pulse from Rounak Jain

March 16, 2024 | 2:51 am

TSLA

Morgan Stanley analyst Adam Jonas is increasingly bullish on Tesla's Optimus humanoid robot venture, highlighting the accelerating interest in humanoid robotics. Jonas notes the recent $675 million funding round for Figure AI by Jeff Bezos, Nvidia, Microsoft, and OpenAI, and the Chinese government's support for humanoid robot technologies. Despite Tesla's stock dipping 34.16% YTD, Jonas maintains an 'overweight' rating on Tesla with a $320 price target, not yet including Optimus's potential. Tesla has demonstrated progress with Optimus, aiming to ship units next year, though Elon Musk acknowledges uncertainties.

Portfolio Pulse from Anan Ashraf

March 16, 2024 | 2:27 am

AMZN

Temu, owned by Pinduoduo Holdings, is shifting its strategy by inviting sellers with U.S.-based warehouses to join its platform, aiming to rival Amazon's delivery speeds. This move from shipping directly from China to utilizing U.S. warehouses is expected to reduce delivery times and allow for the sale of bulkier, more expensive items. Despite the interest from Amazon sellers, early adopters on Temu are mainly Chinese sellers with U.S. storage. This strategy positions Temu as a strong competitor against established e-commerce giants like Amazon.

Portfolio Pulse from Michael Cohen

March 15, 2024 | 9:30 pm

NVDA

SMH

SPY

TSM

Reddit's WallStreetBets has highlighted Nvidia (NVDA), SPY ETF, and Taiwan Semiconductor (TSM) as top trending stocks this week. NVDA leads with over 6,700 mentions, buoyed by anticipation for its AI conference. SPY saw interest due to inflation data, with many traders buying puts. TSM, a key NVDA supplier, also gained attention ahead of its earnings report and the NVDA conference. The VanEck Semiconductor ETF (SMH), which includes NVDA and TSM, is noted for its significant gains.

Portfolio Pulse from Erica Kollmann

March 15, 2024 | 8:49 pm

CSTL

Castle Biosciences announced new data showing its IDgenetix test, which includes drug-drug interactions and lifestyle factors, improves medication recommendations for patients 65 and older with mental health conditions. The study, to be presented at the AAGP Annual Meeting, highlights the test's ability to guide clinicians in selecting optimal neuropsychiatric medications, emphasizing its importance in managing polypharmacy in the elderly. IDgenetix, reimbursed by Medicare for eight mental health conditions, combines genetic information with drug interactions and lifestyle factors to enhance treatment plans.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 8:34 pm

ACON

Aclarion, Inc. shares surged following the announcement of a European patent grant for a system and method in Magnetic Resonance Spectroscopy for diagnosing pain.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 8:04 pm

ACON

Aclarion, Inc. has received approval for European Patent Number EP3928695, which covers a system and method for diagnosing pain using magnetic resonance spectroscopy. This patent strengthens Aclarion's intellectual property portfolio and positions the company for further growth in the European market.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 8:01 pm

REGN

Investors have shown a predominantly bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN), as evidenced by recent options trading activity. Benzinga's options scanner revealed 9 unusual trades, with a sentiment split of 11% bullish and 88% bearish. The trades focus on a price range between $690 and $965. The company, known for its products in eye disease, cardiovascular disease, cancer, and inflammation, has seen its stock price slightly decrease by -0.03% to $958.71. Analyst ratings in the last 30 days have set an average price target of $1137.25 for REGN.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 8:01 pm

CCJ

DNN

URG

UUUU

Uranium stocks, including CCJ, DNN, URG, and UUUU, are trading higher following Kazatomprom's report of full-year profit and a forecast indicating that global uranium output will not meet market demands this decade.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 7:59 pm